Table 2. Prevalence of combined, primary, and acquired resistance to antituberculosis drugs and HIV infection among participants in the Second National Survey on Antituberculosis Drug Resistance, in Porto Alegre, Brazil. 2006-2007.
| Variable | No history of TB treatment | History of TB treatment | Combined resistance | ||||||
|---|---|---|---|---|---|---|---|---|---|
| (primary resistance) | (acquired resistance) | ||||||||
| n | Prevalence, % | 95% CI | n | Prevalence, % | 95% CI | n | Prevalence, % | 95% CI | |
| Drug susceptibility | 224 | 91.5 | 87.9-95.2 | 75 | 68.0 | 57.2-78.8 | 299 | 85.6 | 81.7-89.7 |
| Any resistance | 224 | 8.5 | 4.8-12.1 | 75 | 32.0 | 21.2- 42.8 | 299 | 14.4 | 10.4-18.4 |
| INH | 224 | 7.1 | 3.7-10.5 | 75 | 29.3 | 18.8-39.9 | 299 | 12.7 | 8.9-16.5 |
| RIF | 224 | 2.2 | 0.3-4.2 | 75 | 13.3 | 5.4-21.2 | 299 | 5.0 | 2.5-7.5 |
| Monoresistance | 224 | 4.9 | 2.0-7.8 | 75 | 18.7 | 9.6-27.7 | 299 | 8.4 | 5.2-11.5 |
| INH | 224 | 4.9 | 2.0-7.8 | 75 | 17.3 | 8.6-26.1 | 299 | 8.0 | 4.9-11.1 |
| RIF | 224 | 0.0 | 0.0-0.0 | 75 | 1.3 | 0.0-3.9 | 299 | 0.3 | 0.0-0.9 |
| Multidrug resistance | |||||||||
| INH+RIF | 224 | 2.2 | 0.3-4.2 | 75 | 12.0 | 4.5-19.5 | 299 | 4.7 | 2.3-7.1 |
| Resistance to 1 drug | 224 | 4.9 | 2.0-7.8 | 75 | 18.7 | 9.6-27.7 | 299 | 8.4 | 5.2-11.5 |
| Resistance to 2 drugs | 224 | 2.2 | 0.3-4.2 | 75 | 12.0 | 4.5-9.5 | 299 | 4.7 | 2.3-7.1 |
| HIV infection | 185 | 23.8 | 17.6-30.0 | 67 | 32.8 | 23.1-44.4 | 252 | 26.2 | 20.7-31.6 |
INH
: isoniazid
RIF
: rifampin